Home › Companies › Xeris Biopharma Holdings, Inc. › 2025-2026

Xeris Biopharma Holdings, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Xeris Biopharma Holdings, Inc.’s Form 8-K, filed 2026-06-05 (Item 5.07 on EDGAR). Page generated 02 October 2026.

8Reported items
227Asset managers
948Fund votes
2026-06-04Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Xeris Biopharma Holdings, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Xeris Biopharma Holdings, Inc.

These tallies are Xeris Biopharma Holdings, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-05 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Xeris Biopharma Holdings, Inc. — official shareholder meeting results, meeting held 2026-06-04
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Dawn Halkuff	62,581,577	--	--	24,906,166	40,780,330	Majority: yes
Elect Director: John Johnson	52,665,077	--	--	34,822,666	40,780,330	Majority: yes

Source: Xeris Biopharma Holdings, Inc., Form 8-K, filed with the SEC on 2026-06-05 — read the filing on EDGAR.

How asset managers voted at the Xeris Biopharma Holdings, Inc. 2025-2026 meeting

Each item below shows how the 227 asset managers that disclosed a Xeris Biopharma Holdings, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Xeris Biopharma Holdings, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTES

Combines 3 wordings of this item as funds reported it.

95% fund support · no official result

FOR 95%

The 215 asset managers below cast 95% of the shares they voted on this item FOR (67,582,204 for, 3,531,046 against).

FOR: 67,582,204 (95.0%)AGAINST: 3,531,046 (5.0%)ABSTAIN: 12,254 (0.0%)NOT VOTED: 20,026 (0.0%)

Largest asset managers voting on “TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS.” at Xeris Biopharma Holdings, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
BlackRock	11,779,207	44,680	0	For
Vanguard	11,013,887	20	3	For
State Street	4,358,114	10,833	0	For
Fidelity	4,053,434	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	3,483,286	0	0	For
Nuveen	3,388,130	0	0	For
TIAA	3,311,894	0	0	For
Charles Schwab	2,927,816	0	0	For
Legal & General Investment Management Ltd	0	1,891,584	0	Against
Wellington	1,484,996	0	0	For
Northern Trust	1,345,292	14,723	0	For
Federated Hermes	1,338,362	0	0	For
Two Sigma	1,263,856	0	0	For
DE Shaw	1,192,476	0	0	For
Voss Capital, LP	1,110,244	0	0	For
Knott David M Jr	1,060,000	0	0	For
Goldman Sachs	1,024,648	0	0	For
KENNEDY CAPITAL MANAGEMENT LLC	844,736	114,325	0	For
Voya	958,524	0	0	For
AQR	764,887	0	0	For
UBS	0	581,790	0	Against
MELLON INVESTMENTS Corp	0	540,213	0	Against
T. Rowe Price	533,605	0	0	For
Roundview Capital LLC	491,244	0	0	For
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND	464,084	0	0	For

Showing the 25 largest of 215 asset managers. See all 215 in the interactive database.

2. To elect two Class II directors to our board of directors to serve until the 2029 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Dawn Halkuff

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

72% Majority: yes · of votes cast

FOR 72%WITHHELD 28%

FOR: 62,581,577WITHHELD: 24,906,166

Xeris Biopharma Holdings, Inc.’s own tally for this item (“Elect Director: Dawn Halkuff”): 62,581,577 for, 24,906,166 withheld, per its Form 8-K filed 2026-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 172,558,783 outstanding shares: 36% for, 14% withheld (50.7% of the company cast a for/withheld vote).

The 60 asset managers below cast 100% of the shares they voted on this item FOR (26,424,881 for, 0 against).

FOR 87%13%

FOR: 26,424,881 (87.3%)ABSTAIN: 3,848,999 (12.7%)

Largest asset managers voting on “To elect two Class II directors to our board of directors to serve until the 2029 Annual Meeting of Stockholde” at Xeris Biopharma Holdings, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	9,573,015	69,814	For
BlackRock	6,040,444	0	For
Fidelity	3,474,721	67,400	For
TIAA	3,311,894	0	For
Charles Schwab	1,463,769	0	For
State Street	1,248	1,096,961	Abstain
Federated Hermes	490,423	0	For
First Trust	0	431,010	Abstain
Voya	0	399,614	Abstain
Bridge Builder Trust	372,451	0	For
Royce	356,000	0	For
Equitable	252,494	90,380	For
QUANTITATIVE MASTER SERIES LLC	251,634	0	For
Victory Capital	0	245,592	Abstain
Janus Detroit Street Trust	0	211,520	Abstain
RBB FUND, INC.	0	207,543	Abstain
Principal Exchange-Traded Funds	0	199,971	Abstain
1290 Funds	0	173,590	Abstain
Lincoln Financial	0	169,954	Abstain
TIFF INVESTMENT PROGRAM	120,395	0	For
Goldman Sachs	113,479	0	For
Northern Trust	95,602	0	For
SEI	93,145	0	For
AIG/SunAmerica	0	84,073	Abstain
Global X	74,612	0	For

Showing the 25 largest of 60 asset managers. See all 60 in the interactive database.

3. To elect two Class II directors to our board of directors to serve until the 2029 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: John Johnson

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

60% Majority: yes · of votes cast

FOR 60%WITHHELD 40%

FOR: 52,665,077WITHHELD: 34,822,666

Xeris Biopharma Holdings, Inc.’s own tally for this item (“Elect Director: John Johnson”): 52,665,077 for, 34,822,666 withheld, per its Form 8-K filed 2026-06-05 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 172,558,783 outstanding shares: 31% for, 20% withheld (50.7% of the company cast a for/withheld vote).

The 60 asset managers below cast 100% of the shares they voted on this item FOR (18,447,196 for, 0 against).

FOR 61%ABSTAIN 39%

FOR: 18,447,196 (60.9%)ABSTAIN: 11,826,684 (39.1%)

Largest asset managers voting on “To elect two Class II directors to our board of directors to serve until the 2029 Annual Meeting of Stockholde” at Xeris Biopharma Holdings, Inc., 2025-2026
Asset manager	For	Abstain	Vote
Vanguard	9,565,464	77,364	For
BlackRock	0	6,040,444	Abstain
Fidelity	2,903,405	638,716	For
TIAA	3,311,894	0	For
Charles Schwab	0	1,463,769	Abstain
State Street	1,096,920	1,289	For
Federated Hermes	490,423	0	For
First Trust	0	431,010	Abstain
Voya	0	399,614	Abstain
Bridge Builder Trust	342,700	29,751	For
Royce	356,000	0	For
Equitable	0	342,874	Abstain
QUANTITATIVE MASTER SERIES LLC	0	251,634	Abstain
Victory Capital	0	245,592	Abstain
Janus Detroit Street Trust	0	211,520	Abstain
RBB FUND, INC.	0	207,543	Abstain
Principal Exchange-Traded Funds	0	199,971	Abstain
1290 Funds	0	173,590	Abstain
Lincoln Financial	105,200	64,754	For
TIFF INVESTMENT PROGRAM	0	120,395	Abstain
Goldman Sachs	113,479	0	For
Northern Trust	95,602	0	For
SEI	0	93,145	Abstain
AIG/SunAmerica	0	84,073	Abstain
Global X	0	74,612	Abstain

Showing the 25 largest of 60 asset managers. See all 60 in the interactive database.

4. TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

AUDIT-RELATED

99.9% fund support · no official result

FOR 99.9%

The 59 asset managers below cast 99.9% of the shares they voted on this item FOR (30,254,304 for, 3 against).

FOR: 30,254,304 (100.0%)AGAINST: 3 (0.0%)ABSTAIN: 1 (0.0%)

Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COM” at Xeris Biopharma Holdings, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	9,642,824	3	1	For
BlackRock	6,040,444	0	0	For
Fidelity	3,542,121	0	0	For
TIAA	3,311,894	0	0	For
Charles Schwab	1,463,769	0	0	For
State Street	1,098,209	0	0	For
Federated Hermes	490,423	0	0	For
First Trust	431,010	0	0	For
Voya	399,614	0	0	For
Bridge Builder Trust	372,451	0	0	For
Royce	356,000	0	0	For
Equitable	342,874	0	0	For
QUANTITATIVE MASTER SERIES LLC	251,634	0	0	For
Victory Capital	245,592	0	0	For
Janus Detroit Street Trust	211,520	0	0	For
RBB FUND, INC.	207,543	0	0	For
Principal Exchange-Traded Funds	199,971	0	0	For
1290 Funds	173,590	0	0	For
Lincoln Financial	169,954	0	0	For
TIFF INVESTMENT PROGRAM	120,395	0	0	For
Goldman Sachs	113,479	0	0	For
Northern Trust	95,602	0	0	For
SEI	93,145	0	0	For
AIG/SunAmerica	84,073	0	0	For
Global X	74,612	0	0	For

Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.

5. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 7 asset managers below cast 100% of the shares they voted on this item FOR (1,589,661 for, 0 against).

FOR: 1,589,661 (100.0%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at Xeris Biopharma Holdings, Inc., 2025-2026
Asset manager	For	Vote
Granahan Investment Management, LLC	771,761	For
ALGERT GLOBAL LLC	609,692	For
GLOBEFLEX CAPITAL L P	123,184	For
FORUM FUNDS II	66,984	For
Empirical Financial Services, LLC d.b.a. Empirical Wealth Ma	13,650	For
Integrated Quantitative Investments LLC	4,390	For
Torrey Growth & Income Advisors	0	--

6. 14A Executive Compensation

AUDIT-RELATED

100% fund support · no official result

FOR 100%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (7,648 for, 0 against).

FOR: 7,648 (100.0%)

Largest asset managers voting on “14A Executive Compensation” at Xeris Biopharma Holdings, Inc., 2025-2026
Asset manager	For	Vote
MQS Management LLC	6,608	For
HARBOUR INVESTMENT MANAGEMENT LLC	1,000	For
McGowan Group Asset Management, Inc.	40	For

7. Ratify Appointment of Independent Auditors

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 100%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (48,453 for, 0 against).

FOR: 48,453 (100.0%)

Largest asset managers voting on “Ratify Appointment of Independent Auditors” at Xeris Biopharma Holdings, Inc., 2025-2026
Asset manager	For	Vote
FORUM FUNDS II	47,413	For
HARBOUR INVESTMENT MANAGEMENT LLC	1,000	For
McGowan Group Asset Management, Inc.	40	For

8. Election of Directors (Majority Voting)

SECTION 14A SAY-ON-PAY VOTES

All nominees (reported as one line). These filers reported the election of directors as a single line covering every nominee. It is not attributed to any one director, and no share total is shown for it.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR.

FOR: 100.0%

Largest asset managers voting on “Election of Directors (Majority Voting)” at Xeris Biopharma Holdings, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
HARBOUR INVESTMENT MANAGEMENT LLC	2,000	0	0	0	For
McGowan Group Asset Management, Inc.	40	0	0	0	For

Largest Xeris Biopharma Holdings, Inc. shareholders voting in 2025-2026

Ranked by the number of Xeris Biopharma Holdings, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 172,558,783 shares outstanding at the time of that meeting.

Top Xeris Biopharma Holdings, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	BlackRock	6.85%
2	Vanguard	6.38%
3	State Street	2.53%
4	Fidelity	2.35%
5	GEODE CAPITAL MANAGEMENT, LLC	2.02%
6	Nuveen	1.96%
7	TIAA	1.92%
8	Charles Schwab	1.70%
9	Legal & General Investment Management Ltd	1.10%
10	Wellington	0.86%

Reported Xeris Biopharma Holdings, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Xeris Biopharma Holdings, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
BlackRock	7.50%	13F
D.E. Shaw	4.51%	13F
State Street	2.70%	13F
Morgan Stanley	1.57%	13F
Wellington Management	1.26%	13F
Two Sigma	1.12%	13F
Goldman Sachs	0.94%	13F

Percentages above are of 172,558,783 shares outstanding, as reported by Xeris Biopharma Holdings, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Xeris Biopharma Holdings, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Xeris Biopharma Holdings, Inc.'s shareholder meeting held 2026-06-04, in the 2025-2026 proxy season, 227 asset managers reported how they voted in their SEC Form N-PX filings, covering 948 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. Xeris Biopharma Holdings, Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. — the reporting funds cast 95% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

Xeris Biopharma Holdings, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).